Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs high-dose radioiodine ablation in low-risk differentiated thyroid cancer
ChiCTR-IOR-15006139Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iodine-131 in well-differentiated thyroid cancer (WDTC), papillary thyroid cancer (PTC) and follicular carcinoma (FTC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Thyroglobulin level, Diagnostic radioiodine scan and 3 more. Started Sep 2014; status: recruiting.
02
Drugs
iodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)papillary thyroid cancer (PTC)follicular carcinoma (FTC)
Beyond the preview
Go deeper on ChiCTR-IOR-15006139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IOR-15006139.